The International Society for Biological Therapy of Cancer (iSBTc) 22nd Annual Meeting: WorkshopNovember 1, 2007Seaport World Trade Center in Boston, MassachusettsProgram OrganizersBernard A. Fox, PhD - Earle A. Chiles Research InstituteThomas F. Gajewski, MD, PhD - University of ChicagoRachel W. Humphrey, MD - Bristol Myers-Squibb CompanyHyam I. Levistsky, MD - Johns Hopkins University, School of MedicineJon M. Wigginton, MD - Merck & Co., IncProgram SummaryDrawing on dialogue initiated among leaders in the field at a highly successful planning workshop sponsored by iSBTc in 2006, this in-depth program provides an assessment of state-of-the-art opportunities for combining immune-stimulating agents with other cancer biologics as well as conventional antineoplastic agents. This highly interactive program will provide a venue for intensive scientific dialogue among key stakeholders regarding both strategic opportunities and central obstacles to realizing the potential of combination approaches for the biological therapy of cancer. Intended AudienceThe target audience for the workshop incorporates basic and clinical investigators from academic, regulatory, and biopharmaceutical venues. The audience includes, researchers, clinicians, post-doctoral fellows, students, and allied health professionals.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org